Basic HTML Version
96
SCIENTIFIC REPORT 2012
Title:
Phase 3, open, randomized, multicenter study of NKTR-102 versus treatment
physician-chosen (TEM) in patients with locally recurrent breast cancer or
metastatic previously treated with an Anthracycline, a Taxane and Capecitabine.
District Attorney:
Nectar Therapeutics.
Principal Investigator:
Miquel Àngel I followed Palmer.
Title:
Multicenter, open, expanded access study for postmenopausal women with
Locally advanced metastatic breast cancer with positive estrogen receptor that have
progressed after previous hormone treatment, which investigates the treatment of everolimus
(RAD001) in combination with exaemestane.
District Attorney:
Novartis Farmacéutica SA
Principal Investigator:
Miquel Àngel I followed Palmer.
Title:
Randomized phase III study, double blind, with parallel and multicenter groups for
compare the efficacy and tolerability of fulvestrant (FASLODEXTM) 500 mg with anastrozole
(ARIMIDEXTM) 1 mg as a hormone treatment for postmenopausal women with cancer
locally advanced or metastatic breast cancer with positive hormone receptors that have not
previously received no hormonal treatment (FALCON).
District Attorney:
Astrazeneca AB.
Principal Investigator:
Miquel Àngel I followed Palmer.
Title:
Multicenter, observational, ambispective study of breast cancer patients
metastatic or locally advanced, treated first-line with bevacizumab, and free of
progression for at least 12 months. LORENA Studio.
District Attorney:
Galician Regional Oncology Center "José Antonio Quiroga y Piñeiro".
Principal Investigator:
Miquel Àngel I followed Palmer.
Title:
Evaluation study of hypertension as a predictive factor of efficacy a
Bevacizumab (BV) in combination with chemotherapy (QT) in metastatic colorectal cancer (CRM) and
in metastatic breast cancer (CMM).
District Attorney:
GEICAM.
Principal Investigator:
Miquel Àngel I followed Palmer.
Title:
Prospective observational study for the evaluation of the impact of the determination of
the intrinsic subtypes of breast cancer using PAM50 with nanostring technology in the
use of adjuvant chemotherapy in women with breast cancer, with hormone receptors
positive and negative nodes.
District Attorney:
NanoString® Technologies, Inc.
Principal Investigator:
Miquel Àngel I followed Palmer.